PLN-74809 + Placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Respiratory Distress Syndrome
Conditions
Acute Respiratory Distress Syndrome, SARS-CoV-2
Trial Timeline
Oct 22, 2020 → Aug 2, 2021
NCT ID
NCT04565249About PLN-74809 + Placebo
PLN-74809 + Placebo is a phase 2 stage product being developed by Pliant Therapeutics for Acute Respiratory Distress Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT04565249. Target conditions include Acute Respiratory Distress Syndrome, SARS-CoV-2.
What happened to similar drugs?
20 of 20 similar drugs in Acute Respiratory Distress Syndrome were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06097260 | Phase 2 | Terminated |
| NCT05621252 | Phase 2 | Completed |
| NCT04565249 | Phase 2 | Terminated |
| NCT04480840 | Phase 2 | Completed |
| NCT04396756 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Respiratory Distress Syndrome